Viral Vector Platforms are the dominant segment, accounting for over 60.3% of the market share in 2024. This dominance is due to their high gene transduction efficiency and long-lasting expression, making them the preferred choice for most FDA-approved therapies.
In vivo approaches deliver therapy directly into the patient's body, while ex vivo methods involve modifying cells outside the body before reinfusion. In vivo gene therapy is the leading delivery mode, holding a 48.26% market share in 2024 due to its simplified logistics and success in treating neurological and ocular diseases.
North America dominates the market with a 35.96% share in 2024. Its leadership is fueled by a high concentration of clinical trials, robust intellectual property protection, and supportive regulatory frameworks such as the FDA’s Fast Track and Orphan Drug designations.
The Asia-Pacific region is the fastest-growing market, with a projected CAGR of 16.37%. Growth is driven by significant investments in biotech infrastructure, government initiatives in countries like China and Japan, and the integration of AI in manufacturing.
CDMOs are becoming essential for scalability and cost reduction. They provide end-to-end solutions from preclinical vector design to GMP manufacturing, helping small and mid-sized biotech companies overcome manufacturing bottlenecks and speed up time-to-market.
AI is being used to design novel capsids and optimize vectors. Tools like BioMap’s xTrimo accelerate AAV capsid design and improve vector distribution efficiency, which enhances delivery precision and reduces development costs.
The most significant restraints include the extremely high cost of treatment (often exceeding USD 2 million per dose), complex GMP manufacturing requirements, and limited reimbursement frameworks, particularly in low- and middle-income economies.
The market is led by major pharmaceutical and biotechnology innovators, including CRISPR Therapeutics, Novartis AG, Spark Therapeutics, Voyager Therapeutics, Gilead Sciences (Kite Pharma), Andelyn Biosciences, and AstraZeneca.
In early 2025, AstraZeneca acquired EsoBiotec for USD 1 billion to scale in vivo cell therapy. Additionally, Andelyn Biosciences expanded its AAV Curator platform, and the UK’s Medical Research Council launched new Centres of Research Excellence to accelerate therapies for untreatable conditions.
